Gluten-free diet in children with recent-onset type 1 diabetes: A 12-month intervention trial

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61388971%3A_____%2F20%3A00531995" target="_blank" >RIV/61388971:_____/20:00531995 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11120/20:43919637 RIV/00216208:11130/20:10404498 RIV/00216208:11320/20:10404498 RIV/00064173:_____/20:N0000068 RIV/00064203:_____/20:10404498

Výsledek na webu

<a href="https://dom-pubs.onlinelibrary.wiley.com/doi/abs/10.1111/dom.13974" target="_blank" >https://dom-pubs.onlinelibrary.wiley.com/doi/abs/10.1111/dom.13974</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1111/dom.13974" target="_blank" >10.1111/dom.13974</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Gluten-free diet in children with recent-onset type 1 diabetes: A 12-month intervention trial

Popis výsledku v původním jazyce

To test whether a gluten-free diet (GFD) is associated with the deceleration of the decline in beta-cell capacity in non-coeliac children with recently diagnosed type 1 diabetes.nForty-five children (aged 10.2 +/- 3.3 years) were recruited into a self-selected intervention trial: 26 started with a GFD within a median of 38 days postonset, whereas 19 remained on a standard diet. The main outcomes were the decline in C-peptide area under the curve (AUC) in mixed-meal tolerance tests (MMTTs) at 6 and 12 months relative to 1 month after diabetes onset and the difference in insulin dose, insulin dose-adjusted A1c (IDAA1c) and HbA1c assessed every 3 months. The adherence to the GFD was verified by immunoreactive gluten in the stool and by food questionnaires at every visit. Questionnaires were administered to the participants at the end of the intervention at 12 months. The data were analysed as per protocol by linear and longitudinal regression models adjusted for sex, age and baseline variables.nAt 12 months, the difference in C-peptide AUC between subjects in the GFD group and controls was 205 pmol/L (95% CI -223 to 633, P = 0.34) in a model adjusted for age, sex and body weight, and for baseline insulin dose, MMTT C-peptide AUC and HbA1c assessed at 1 month after diagnosis. In a longitudinal analysis of all three time points adjusted for age, sex and body weight, C-peptide declined more slowly in the GFD group than in controls, with the difference in trends being 409 pmol/L/year (P = 0.04). The GFD group had a marginally lower insulin dose (by 0.15 U/kg/day, P = 0.07), a lower IDAA1c (by 1.37, P = 0.01) and a lower mean HbA1c (by 0.7% [7.8 mmol/mol], P = 0.02) than those of the controls at 12 months. There was no appreciable difference between the groups in daily carbohydrate intake (P = 0.49) or in the QoL reported by the patients (P = 0.70) and their parents/caregivers (P = 0.59).nn

Název v anglickém jazyce

Gluten-free diet in children with recent-onset type 1 diabetes: A 12-month intervention trial

Popis výsledku anglicky

To test whether a gluten-free diet (GFD) is associated with the deceleration of the decline in beta-cell capacity in non-coeliac children with recently diagnosed type 1 diabetes.nForty-five children (aged 10.2 +/- 3.3 years) were recruited into a self-selected intervention trial: 26 started with a GFD within a median of 38 days postonset, whereas 19 remained on a standard diet. The main outcomes were the decline in C-peptide area under the curve (AUC) in mixed-meal tolerance tests (MMTTs) at 6 and 12 months relative to 1 month after diabetes onset and the difference in insulin dose, insulin dose-adjusted A1c (IDAA1c) and HbA1c assessed every 3 months. The adherence to the GFD was verified by immunoreactive gluten in the stool and by food questionnaires at every visit. Questionnaires were administered to the participants at the end of the intervention at 12 months. The data were analysed as per protocol by linear and longitudinal regression models adjusted for sex, age and baseline variables.nAt 12 months, the difference in C-peptide AUC between subjects in the GFD group and controls was 205 pmol/L (95% CI -223 to 633, P = 0.34) in a model adjusted for age, sex and body weight, and for baseline insulin dose, MMTT C-peptide AUC and HbA1c assessed at 1 month after diagnosis. In a longitudinal analysis of all three time points adjusted for age, sex and body weight, C-peptide declined more slowly in the GFD group than in controls, with the difference in trends being 409 pmol/L/year (P = 0.04). The GFD group had a marginally lower insulin dose (by 0.15 U/kg/day, P = 0.07), a lower IDAA1c (by 1.37, P = 0.01) and a lower mean HbA1c (by 0.7% [7.8 mmol/mol], P = 0.02) than those of the controls at 12 months. There was no appreciable difference between the groups in daily carbohydrate intake (P = 0.49) or in the QoL reported by the patients (P = 0.70) and their parents/caregivers (P = 0.59).nn

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

10606 - Microbiology

Projekt

<a href="/cs/project/NV16-27994A" target="_blank" >NV16-27994A: Vliv bezlepkové diety na reziduální kapacitu beta buněk, imunitní funkce a střevní mikrobiom u dětí s nově manifestovaným diabetem 1. typu</a><br>

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2020

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Diabetes Obesity & Metabolism

ISSN

1462-8902

e-ISSN

—

Svazek periodika

22

Číslo periodika v rámci svazku

5

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

7

Strana od-do

866-872

Kód UT WoS článku

000522664600017

EID výsledku v databázi Scopus

2-s2.0-85079159686